Company Overview of Alvogen, Inc.
Alvogen, Inc. manufactures generic and brand medicines, biosimilars, and over the counter (OTC) medicines. The company focuses on niche generics, pathces, controlled releases, and narcotics in various forms, including solid oral dosage forms, soft gelatin capsules, modified release tablets, transdermals, creams, ointments, and injectables. Its portfolio includes a range of molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology, and gastroenterology. The company also sells and markets a portfolio of OTC medicines and medical devices. In addition, it promotes and distributes a range of biosimilar products in various therapeutic areas; and offers...
10 Bloomfield Avenue
Pine Brook, NJ 07058
Founded in 2008
Key Executives for Alvogen, Inc.
Executive Chairman and Chief Executive Officer
Chief Operating Officer and Member of Executive Board
Member of Executive Board and Chief Executive Officer of Alvogen America
President of Alvogen America
Compensation as of Fiscal Year 2016.
Alvogen, Inc. Key Developments
Alvogen Launches First Generic Equivalent of Copaxone™ in Europe
Sep 5 16
Alvogen announced the launch of Remurel™ the first generic equivalent of Copaxone™ in Central and Eastern Europe. The product will be marketed as a once daily subcutaneous 20 mg prefilled syringe under the brand name Remurel™ and will be launched throughout all Central and Eastern European countries from September 2016 onwards. The product will be launched with a proprietary auto-injector device having multiple features to help support MS patients in their treatment with Remurel™. Teva‘s Copaxone™ delivered sales of over EUR 510 million in Europe in 2015.
Alvogen, Inc. Launches First Generic Equivalent of Zoladex
May 4 16
Alvogen Inc. announced the launch of the first generic equivalent of Zoladex™ in Central and Eastern Europe. The product will be marketed in two strengths (3.6mg and 10.8mg) under the brand name Reseligo™ and will be launched in Bulgaria, Croatia, Baltics, Romania, Hungary, Iceland and Poland from May 2016. Reseligo™ contains the active ingredient goserelin and belongs to the class of GnRH agonists (analogues of gonadotropin releasing hormone) which interfere with the regulation of the sex hormone balance. As a consequence, testosterone levels are lowered in men and estradiol levels are lowered in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormonesensitive tumors such as prostate cancer or breast cancer with goserelin. In addition, goserelin is used to treat certain benign gynecological disorders. Goserelin is administered in the form of a biodegradable implant which releases the active ingredient over a period of either one or three months.
Alvogen and Natco Settle Infringement Suit with Gilead and Others for Generic Tamiflu
Dec 14 15
Natco Pharma Limited and Alvogen announced that they have settled the patent infringement suit filed by Gilead Sciences Inc., Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ltd. and Genentech Inc. against Alvogen and Natco in New Jersey District Court (2:11-cv-04969-SDWMCA). FDA granted tentative approval to NATCO for the generic oseltamivir phosphate capsules on March 14, 2014. Under the terms of the settlement, NATCO's partner Alvogen will be able to market the oseltamivir phosphate capsules before the expiration of the pediatric exclusivity period listed in FDA's Orange Book for U.S. Patent No. 5,763,483, which is February 23, 2017.
Similar Private Companies By Industry
Recent Private Companies Transactions